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We are working to produce a stable and effective hemoglobin-based oxygen carrier (HBOC) 
for critical care. Mammalian myoglobins are good model systems for the protein engineering of 
human hemoglobin, and in the current work, our aim is to generate a circularly permuted myoglobin 
with increased thermodynamic stability compared to previous permuteins characterized by our lab. 
Our initial permuted myoglobin, HGL16, includes a 16-residue Gly-Ser linker (SGGG)4 between the A 
and H helices in sperm whale myoglobin (swMb). Although HGL16 was shown to fold and function 
like wild-type swMb, its stability was reduced significantly. In the current work, computational 
design of the linker was employed, with the aim of increasing the stability of the permutein. The 
design modeled the linker as a helix, and includes novel interactions with the swMb framework. The 
resulting permutant, ML1, appears to be less stable than HGL16, but appears to refold properly from 
inclusion bodies based on the visible spectrum of the cyanomet isoform. In addition, we have 
generated a single-chain human hemoglobin (scHb) using shorter linkers between subunits. The 
scHb design includes a single glycine residue as the linker between the two α-globins and novel 
covalent connections between each α-globin and a permuted β-globin. To be utilized as the 
framework for a therapeutically useful HBOC, scHb must possess similar function and structure to 
authentic human hemoglobin (HbA). Functional studies indicate that scHb possesses highly similar 
ligand affinity to HbA in the R-state, but has an iron with increased reactivity in the T-state. Analysis 
by 1H NMR indicates that the heme binding pocket and the α1β1 interface in scHb have structures 
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 Necessity for a red blood cell substitute. The 2011 national blood collection and utilization 
survey reported a decreasing margin between available units of blood collected and number of units 
transfused. Between 2001 and 2008, the rate of units transfused was increasing at a slower rate 
than available supply (1). Between 2008 and 2011, there was a comparable decrease in the supply 
and units transfused (1). However, data from 2011 showed a greater decrease in available supply 









Figure 1. Allogeneic whole blood and red blood cell collections and transfusions from 1989-2011. The 
figure compares total donated blood (diamonds), total available supply (excludes supply rejected 
after testing – triangles), and the number of units transfused (circles) (1).  
In response to this shrinking margin, significant research has focused on the development of 
a red blood cell (RBC) substitute. RBCs possess several distinct characteristics that make them ideal 
for their primary function of transporting oxygen throughout the body. They contain high 
concentrations of hemoglobin (Hb) encapsulated within a cell that protects the protein from 
degradation, as well as protecting tissues from oxidative damage (2). RBCs also encapsulate a 
number of other proteins that assist in function and prevention of toxicity, such as methemoglobin 
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reductase. Methemoglobin reductase prevents buildup of the oxidized form of Hb (Fe3+ vs. Fe2+), 
which is unable to bind oxygen. Another important enzyme found in RBCs is superoxide dismutase 
(SOD) which catalyzes the breakdown of superoxide (O2-). In addition, RBCs contain high 
concentrations of allosteric effectors such as 2,3-bisphospho-D-glycerate (2,3-BPG) that help 
modulate oxygen binding affinity. An ideal RBC substitute must be manufactured economically and 
in large quantities, be stable in vivo, possess oxygen carrying properties comparable to whole blood, 
and be non-toxic (2-7).  
Approaches to creating an RBC substitute. Three main classes of RBC substitutes have 
actively been pursued. The first are perfluorocarbon emulsions, typically composed of a linear or 
cyclic carbon backbone highly substituted with fluorine and occasionally other halogens (Figure 2). 
Perfluorocarbons are chemically and biologically inert and have the ability to transport gases, 
including O2 and CO2, at significantly higher concentrations than aqueous buffers. Considerable 
interest has been generated by perfluorocarbon emulsions because they are relatively cheap, easy 
to produce in large quantities, and have minimal risk of infection and immunogenicity (2). An 
apparent drawback to the use of perfluorocarbons for O2 transport is that they are insoluble in 
aqueous buffers and therefore not well-suited for intravenous administration. To overcome their 
insolubility, perfluorocarbons are prepared as emulsions by mixing with a surfactant, most 
commonly phospholipids (2). Although the perfluorocarbons are biologically inert themselves, 
toxicity issues arise from the surfactant used to prepare the emulsion. The emulsions’ capacity for 
O2 is 3 mL/dL, a considerable increase compared to plasma (2). The amount of O2 dissolved by 
perfluorocarbons is directly proportional to the pO2 (2). This quality has the potential to be 
advantageous if the patient can be provided with high levels of fractional inspired oxygen (FiO2) in 









Figure 2. Examples of perfluorocarbon O2 carriers studied in clinical trials: A) perfluorodecalin; B) 
Fluosol-DA; C) dichloroperfluorooctane; and D) perfluorooctyl bromide (perflubron).  
 
 Another class of RBC substitutes is liposome encapsulated Hb (LEHb), typically composed of 
a phosphatidylcholine bilayer containing a concentrated Hb solution (Figure 3). The appeal of LEHb 
is that it more closely mimics the size of RBCs. There is a protective membrane that prevents Hb 
from degradation. The liposome encapsulation also serves to protect tissue from oxidative damage 
and results in an increased circulatory half-life compared to other RBC substitutes (2). A large 
advantage is the ability to include the alloseric effector 2,3-BPG, methemoglobin reductase, and 
SOD within the liposome. A major drawback is the difficulty of creating liposomes of uniform size 
(2). Furthermore, LEHb is cleared by the reticuloendothelial system (RES), which can potentially pose 















The most-studied class of RBC substitutes is extracellular hemoglobin-based oxygen carrying 
(HBOC) solutions. The primary design criterion for an HBOC is that it possesses reversible O2 binding 
behavior that mimics O2 delivery by RBCs. As shown in Figure 4, the primary advantage of HBOCs 
compared to perfluorocarbons, is their efficient transport of O2 under physiological conditions (2).  
The major shortcoming of donated blood is that it has a shelf life of only a few weeks, with 
mounting evidence to suggest that the incidence of adverse events following transfusion is 
correlated with increased time between collection and administration of a unit of blood (3,4). 
Because cell-free HBOCs are less complex in composition, and can be formulated with anti-oxidants, 
they have a longer shelf-life than RBCs (5). HBOCs also eliminate the need for blood-typing or cross 
matching, and could therefore be administered by emergency medical personnel at the site of an 
accident, rather than after transport to a medical facility (3). Thus, a trauma patient would receive 
oxygen-carrying fluids significantly earlier than is possible by current transfusion protocols. 
 
Figure 4. Comparison of O2 dissociation curves of several types of RBC substitutes and human RBCs. 
Represented are PEG-Hb (an HBOC conjugated with polyethylene glycol), human RBCs, αα-crosslinked 
Hb (a covalently crosslinked HBOC generated by recombinant technology), O-raffinose polymerized 





Challenges associated with HBOCs. The first challenge associated with the development of 
HBOCs is the source of starting material. Three primary sources exist: human RBCs from outdated 
donated blood, bovine RBCs, and hemoglobin produced by recombinant technology (6). The product 
manufactured from human RBCs is limited by the availability of an outdated supply. Approximately 
5-10% of human RBCs become outdated (11), leaving very little starting material to satisfy the need 
for an HBOC manufactured by this method. In contrast, bovine RBCs are plentiful. Rigorous testing is 
performed on donated blood to essentially eliminate the possibility of infection by human 
pathogens. However, both human and bovine RBCs are derived from sources which can be infected 
by mammalian pathogens (2,6). Such screening makes it unlikely that contaminated human RBCs 
will be administered to a patient. Nonetheless, even the remote possibility of infection by HIV or 
hepatitis viruses has resulted in a significant change in transfusion practices. Transfusion is viewed 
as a high-risk procedure by both patients and physicians (1,11). Concerns with using bovine Hb to 
make an HBOC include the possibility of contamination with bovine prions, which can cause variant 
Creutzfeldt-Jakob disease in humans (9,12).  
An alternate starting material, recombinant Hb, was first described by Nagai and Thorgersen 
in 1984 (13,14). Their strategy was to express β-globin as a cleavable fusion protein, purify the 
fusion protein, and cleave the fusion junction using blood coagulation factor Xa (14). The isolated β-
globin was reconstituted with heme and α-subunits to form fully folded α2β2 tetramer (14). In 1990, 
a simplified method for recombinant Hb expression was developed by Hoffman et al. (15). This 
method utilized an expression plasmid encoding both β- and α-globin genes, which were 
coexpressed in E. coli with addition of supplemental hemin. α- and β-chains folded correctly into 
fully functioning holo-rHb tetramers in vivo (15). This method was also successfully applied to Hb 
expression in S. cerevisiae (16), however most researchers abandoned the yeast system due to 




were reported for holo-rHb expression in E. coli (17,19). This method of production minimizes 
exposure of the HBOC preparation to human pathogens; however, the bovine hemin used to 
supplement the bacterial culture must be treated to remove any potential pathogens (2).  
Although bacterial fermentation presents the possibility of a limitless supply of hemoglobin 
as starting material for an HBOC, the purification of recombinant Hb from bacterial lysate is 
significantly more complex than purifying Hb from erythrocytes. Because a high dosage of the 
recombinant protein is required, very little contaminant can be tolerated (2). Recombinant 
hemoglobin must be 99.999% pure to be safe for injection in humans.  
 Cell-free hemoglobin has a higher affinity for oxygen compared to hemoglobin in RBCs, 
because the negative allosteric effector 2,3-BPG exists in high concentrations in erythrocytes and 
functions to decrease O2 affinity to the physiologically optimum range (2,9). Cell-free Hb will not be 
bound by 2,3-BPG due to its low concentration in blood plasma. Thus a cell-free Hb must be 
chemically modified, or contain specific mutations, to decrease its O2 affinity. Both strategies have 
been employed in the development of HBOCs (2,7,9).  
The formation of methemoglobin, the Fe3+ form of Hb, is increased in cell-free Hb solutions. 
Unlike Fe2+ Hb, methemoglobin cannot bind O2 reversibly. Within RBCs, the presence of 
methemoglobin reductase and other antioxidants act to reduce the ferric heme to the functional 
ferrous form, and also protect against the formation of reactive oxygen species and heme release. 
When the oxidation of iron from Fe2+ to Fe3+ occurs, the bond between the heme and the ε-NH of 
the proximal histidine weakens, resulting in increased rates of heme dissociation (22). Free heme 




There are two mechanisms of reaction that lead to the autooxidation of oxy-Hb. The first is 
direct dissociation of a superoxide anion (20): 
(1) Hb(Fe2+)O2 → Hb(Fe3+) + O2-·  
The second mechanism for autoxidation is through nucleophilic displacement, where O2 dissociates 
from ferrous heme and a nucleophile (Nu; the distal histidine is thought to act as the nucleophile) 
binds to the unliganded iron ion. An electron from the ferrous iron is then transferred to the 
dissociated O2, forming the ferric state (21): 
(2) HbO2 ↔ Hb(Fe2+) + O2 
(3) Hb(Fe2+) + Nu ↔ Hb(Fe2+)(Nu) 
(4) Hb(Fe2+)(Nu) + O2 → Hb(Fe3+)Nu + O2-· 
If superoxide formation occurs within RBCs, superoxide dismutase (SOD) is present to break down 
this free radical. However, the mass of Hb administered in a single therapeutic dose (~ 100 g of Hb) 
could overwhelm the antioxidants in the plasma if a significant fraction of the cell-free Hb were 
oxidized. Thus, any modifications made to Hb to optimize functional properties (e.g., mutations or 
chemical crosslinks) must not increase the rate of methemoglobin formation.        
 Intravenous injection of 100 g of cell-free Hb will cause renal damage (2,3,5,7-9). It is normal 
to find free Hb at low concentration in blood plasma, due to the steady rate of hemolysis of RBCs. As 
RBCs age, they are more susceptible to hemolysis, and the Hb released from lysed RBCs acts to 
stimulate the production of new RBCs. Typically, Hb and its breakdown products in circulation are 
removed by other proteins in the plasma. Haptoglobin, hemopexin or albumin, and transferrin are 
able to bind, respectively, to circulating Hb dimers, heme, and iron (8,23). The resulting Hb-bound 




by excretion. However, if these plasma proteins become saturated as a result of excess Hb in 
circulation, the persisting Hb accumulates in kidney tissue (8,24,25). Within erythrocytes, Hb is 
densely packed and stable as a 64 kDa heterotetramer (α2β2). Cell-free Hb is more dilute in blood 
plasma, thus it has greater propensity to dissociate into 32 kDa αβ heterodimers (24). The 
heterodimer is small enough to be filtered by the kidney and accumulate in the proximal tubule, 
causing renal toxicity (24,26).      
 In preclinical studies, and in human safety trials, the intravenous (IV) injection of 
extracellular Hb has been shown to cause hypertensive effects (also known as a “pressor response”) 
(2,7-9,27). Further investigation has revealed the pressor response to be the result of nitric oxide 
(NO) scavenging in extravascular tissues (7,28). NO participates in diverse biological functions, 
including the regulation of blood pressure, as a chemical messenger and as an initiator of 
biochemical cascades (29). The major mechanism of NO scavenging is the oxidation of NO to NO32- 
by oxyhemoglobin (30). In addition, both ferrous and ferric Hb can bind NO tightly, resulting in 
further depletion of NO in the endothelial cells surrounding the vasculature (31). This presupposes 
that Hb extravasation is the first step in a series of events that leads to the pressor response. If so, 
decreasing the rate of HBOC extravasation should attenuate the pressor response (32,33).       
 Support for this hypothesis comes from the data shown in Figure 5, which show that larger 
molecular weight Hbs attenuate the pressor response in conscious rats (34). The HBOCs used in this 
study included the 64 kDa rHb1.1, a 130 kDa “di-Hb”, and a 260 kDa “tetra-Hb”. The two higher 
mass Hbs showed marked reduction of the pressor response compared to the 64 kDa Hb.  
 A similar reduction in the pressor response has been reported for ultrahigh molecular 
weight Hbs produced via chemical crosslinking with glutaraldehyde (35,37). Thus the hypothesis that 




of chemically crosslinked Hbs yield a polydisperse product containing a wide range of polymeric 
species. The use of recombinant technology would allow the generation of poly-Hbs of defined 
molecular weight, as well as allowing site-directed mutations to improve HBOC function (6). 
 
Figure 5. Changes in mean arterial pressure induced by intravenous introduction of HBOCs into 
conscious rats. Represented are a 64 kDa HBOC – rHb 1.1 (orange triangles); a 130 kDa “di-Hb” (blue 
circles); a 260 kDa “tetra-Hb” (green crosses); and human serum albumin to serve as a volume control 
(50 mg/mL, purple squares) (34).   
 
 The ideal HBOC. An ideal HBOC must address all challenges having to do with production, 
stability and function, toxicity, and side effects associated with NO scavenging (e.g., the pressor 
response). An HBOC must be manufactured in massive quantities at a unit cost comparable to that 
for a unit of donated blood (~ $600-1000) (6). Its functional characteristics should mimic those of 
whole blood, such that its binding and release of O2 occur in a physiologically efficacious range (2,9). 
The formation of methemoglobin and free radicals must also be minimized, possibly by the 
incorporation of superoxide dismutase linked to the HBOC. The HBOC must not be filtered by the 
kidneys, and NO scavenging must be attenuated. Both of these issues may be resolved by the 




Types of modified Hb. Chemical crosslinking of Hb is the most common method employed 
for generating novel intra- and intermolecular covalent linkages in HBOCs. The HBOCs produced in 
this fashion are shown schematically in Figure 6, and include surface-modified, cross-linked mono-
Hbs, and polymerized Hbs (2,35). Surface-modified Hb is produced by conjugation of a 
macromolecule, such as polyethylene glycol (PEG) or polyoxyethylene (POE), to lysine residues on 
the Hb surface (2). Conjugation with the macromolecules serves two primary purposes: to stabilize 
the tetramer against subunit dissociation, and increase the hydrodynamic radius (to slow 
extravasation). Added benefits to this design include a decrease in immunogenicity (38), and an 
increase in viscosity and oncotic pressure, which may prove to be clinically useful traits (2).  
Chemically cross-linked hemoglobins include intramolecular linkages that stabilize the Hb 
tetramer (Figure 6). One example of a chemical cross-linker is bis-(3,5-dibromosalicyl) fumarate, 
which reacts with lysine residues in the α-globins (39). This chemical linker is able to specifically bind 
α1Lys-99 and α2Lys-99 when Hb is in the deoxy form. The cross-linked Hb remains highly cooperative 
with a Hill coefficient of 2.6 (39). The oxygen affinity is decreased approximately 2-fold, whereas the 


















Figure 6. Three examples of HBOCs designed to minimize adverse side effects. Top: Surface 
conjugated 64 kDa Hb containing polyethylene glycol and polyoxyethylene. Middle: Chemically or 
genetically cross-linked Hb. Bottom: Polymerized Hb with intermolecular crosslinks. Adapted from 
Stowell et al. (2).      
 
Intrasubunit crosslinks can also be incorporated by gene fusion. As shown in Figure 7, the 
recombinant human hemoglobin produced by Somatogen Inc., rHb1.1, uses a single glycine residue 
to link the α1-α2 termini (40). The covalent fusion of the α-globins prevents dissociation of rHb1.1 
into αβ dimers, and thereby prevents renal toxicity (40). The β globin subunits in rHb1.1 also carry a 













Figure 7. Image of α1-α2 termini fused by a single glycine residue, rHb1.1 (pdb ID 1C7C). 
 The crosslinking of surface lysines by glutaraldehyde results in formation of Hb oligomers of 
various structures and molecular weights (2). The advantage of polymerized Hbs is their increase in 
size, which helps prevent extravasation and kidney filtration. A common problem is the difficulty to 
control precisely the molecular weight distribution of the final product (2,42).  
Engineering and design strategies – single-chain hemoglobin. The studies reviewed above 
illustrate the challenges and advantages of fusing the α- or β-chains using recombinant or chemical 
crosslinking methods; however, no study has yet examined the effect of fusing all four Hb subunits 
to create a single-chain Hb (scHb). Additionally, none of these studies has described the 
consequence of directly fusing the α- and β- chains. There are several potential advantages to the 
generation of a cell-free HBOC derived from a scHb. First, like rHb1.1, a recombinant scHb would 
prevent the dissociation of the tetramer into αβ dimers. Second, a scHb simplifies the production of 
genes for ultrahigh molecular weight poly-Hbs and guarantees a monodisperse product. Third, scHb 
represents a therapeutically useful scaffold to be used for fusion to other proteins such as 
superoxide dismutase, which would increase the size of the protein as well as prevent buildup of 
harmful superoxide anions in cases of tissue reperfusion following prolonged ischemia (O2 
starvation).  
α1  





The most straightforward method of connecting the four globins is to link the termini in 
series with three peptide linkers. The termini between the two α-globins are approximately 2 Å 
apart (Figure 8) and have been linked successfully by Looker et al. using a single glycine residue (40). 
Insertion of a linker between the α- and β- termini has not been reported, and may prove difficult 
because the distance between them is approximately 50 Å (Figure 8). A linker of that length is likely 
to complicate the folding of a polymeric Hb, due to many opportunities for “domain swapping” (41).  
 
Figure 8. Illustration of distances between termini of Hb subunits, as observed in crystal structures. 
Left: Approximately 2 Å separates the α1-α2 termini, which can be linked by one or two residues. 
Right: Approximately 50 Å distance separates the α1-β1 termini.   
 
Our strategy to achieve covalent connection of the α- and β-globins is to employ circular 
permutation of the β-globin. The effect of circular permutation can be understood by imagining the 
connection of the native N- and C-termini with a novel peptide linker, followed by cleavage of the 





















Figure 9. A cartoon representation of the circular permutation process of β-globin. The letters A-H 
signify different helices within the subunit. The bottom figure represents a hypothetical circularized 
protein.     
 
By introducing a linker between native N- and C-termini, the β-globin termini can be 
relocated to the α1-β1 interface in hemoglobin, allowing for insertion of the entire permuted β-
globin sequence into the G-H loop of the α-globin. Closer examination of the Hb crystal structure 
shows that the G-H loops of both α1 and β1 subunits are located on the globin surface and are 
separated by less than 15 Å (Figure 10). In the past, circular permutation has been successfully 
applied to both human α-globin (43) and sperm whale myoglobin (swMb) (44,48), which 
demonstrates that globins can tolerate permutation. Another reason to fuse the globins at the α1β1 
interface is that this interface remains essentially static during R to T transitions, unlike the α1β2 
interface, which is extensively remodeled (49). Additionally, the globin fold and function has been 
shown to tolerate circular permutation and extensive crosslinking (43,44,48,50-55).          
 
 
“circularize protein” (add linker  
between N- and C- termini) 
create N- and C- termini at a new 












Figure 10. The α1β1 subunits above (the image on the right is a 90o rotation of the image on the left) 
highlight the proximity of the G-H loops in the α- and β-subunits. The G-H loop in β-globin, which will 
serve as the new location of termini in the circular permutant, is colored orange. The G-H loop in α-
globin is colored green. These loops are approximately 15 Å apart and can be fused by a peptide 
linker of 5 amino acids in length once the β-globin is circularly permuted.  
Myoglobin as a model system. To assist in the design of an optimal β-hemoglobin 
permutein, myoglobin has been employed as a model system. Sperm whale myoglobin (swMb) is a 
well-characterized structural and functional homolog of human hemoglobin. As such, it has been 
shown to be a good model to understand the effects of point mutations on hemoglobin function 
(10). Thus, we have used Mb to test the effects of permutation on globin structure, stability, and 
function (44). 
 Properties of an optimal linker. When designing a circular permutein, a peptide linker of the 
proper length and flexibility must be inserted between the N- and C-termini of the parent protein. If 
the linker is too short, it induces conformational strain. If it is too long, increased conformational 
entropy can destabilize the permutant as well as reducing control over subunit assembly.  
 The first circularly permuted swMb produced in our lab, called “HGL16”, included a flexible 
16 residue linker with the sequence, (GGGS)4 inserted between the native termini (44). Figure 11 




as determined by one- and two-dimensional NMR (44). Stopped-flow methods were utilized to 
assess ligand binding function, which proved to be essentially identical to that for wild-type swMb 
(see Table 1). However, the permutein showed a decreased stability by ~5 kcal/mol (Table 2). 
Several HGLx permutants were generated to assess the effects of varying linker length and amino 
acid composition on permutein stability. The stabilities of these linker variants were not significantly 






Figure 11. Left: the X-ray crystal structure of wild-type swMb. Right: a model of circularly permuted 
swMb (“HGL16”) with a 16 residue linker inserted between the native N- and C- termini, and novel 













































Table 1. Ligand binding rate constants and equilibrium 
constants for HGL16 and wild-type swMb. Ligand binding 
data were measured by stopped flow methods (44). 
Numbers in parenthesis are values reported by Rohlfs et 
al. (57).  
Parameter HGL16 wt swMb 
CO kon ∙ 10-6 (M-1s-1) 0.63 0.50 (0.50) 
CO koff (s-1) 0.017 0.021 (0.018) 
KCO ∙ 10-6 (M-1) 37 24 (28) 
O2 kon ∙ 10-6 (M-1s-1) 18 16 (16) 
O2 koff (s-1) 15 18 (17) 
KO2 ∙ 10-6 (M-1) 1.2 0.89 (0.9) 
Table 2. Thermodynamic stability parameters for 
HGL16 and wild-type swMb calculated from urea 
denaturation experiments. Values listed are averaged 
over 3-4 separate experiments (44). 
Parameter HGL16 wt swMb 
ΔG°H2O (kcal∙mol-1) 7.2 ± 0.5 12.4 ± 1.6 
mg (kcal∙mol-1∙M-1) -1.65 ± 0.11 -1.83 ± 0.23 













In the current work, focus is shifted towards the design of a structured linker in the hope 
that it will increase permutein stability. Computational methods were employed to assist in the 
design of more complex linkers with stable structures (45,46). Using RosettaDesign software, three 
circularly permuted swMb models were generated. All three of these designs include an α-helical 
linker between native termini, rather than a long flexible chain as in HGL16. Additionally, the designs 
include mutations made to the Mb framework to create novel interactions with the linker (Figure 
12). If any of these models prove to increase the stability of the permutein, their design will inform a 
similar linker re-design for permuted Hbs. 
 
Table 3. Stability parameters of HGLx permuteins 
with varied linkers. ΔΔGoH20 = ΔGmut- ΔGwt, such that a 
more negative value indicates a greater 
destabilization relative to wild-type. 
Protein Linker ΔΔGoH20 (kcal/mol) 
WT - 0 
HGL 6 SGGSGG  -6.2  ± 0.8 
HGL 7 SGGGSGG  -5.4 ± 0.9 
HGL 8 SGGSGSGG  -4.2 ± 0.7 
HGL 9 SGGSGGSGG  -4.8 ± 0.9 
HGL 16 (SGGG)4  -5.0 ± 0.7 
HGL PP12 (P)12  -7.0 ± 1.5 




       
Figure 12. Representations of linker structures as predicted by RosettaDesign are shown above. 
Panels A, B, and C (ML1, ML2, and ML3, respectively) illustrate circularly permuted swMb with the 
designed linker shown as spheres. The ruby spheres indicate hydrophilic residues and the yellow 
indicate hydrophobic residues within the linker. The dark blue spheres represent hydrophilic 
mutations and the light blue spheres are hydrophobic mutations made to the swMb framework. The 
mutations have been made in such a way to support the hydrophobic packing between the linker and 
the permutein. Panel D highlights the helical design of ML1 (47). 
Progress toward the generation of scHb. To achieve the goal of generating a therapeutically 







Figure 13. Scheme for the generation of scHb: starting with αcpβ (top), then linking α- and cpβ-globin 
to create sc-αcpβ (middle), followed by the insertion of a linker between α1-α2 termini to create scHb 
(bottom). See text below for the definitions of these terms.   
The initial design included circular permutation of the β-globin (cpβ) to allow co-expression 
with α-globin (αcpβ) (58). The linker between native N- and C-termini is eight residues in length with 
the sequence Gly-Ser-Gly-Gly-Gln-Gly-Gly-Gly. The αcpβ construct is significantly less stable than 
recombinant wild-type hemoglobin (as shown by decreased soluble protein yields) (58). According 
to analytical HPSEC, co-expression appears to yield α1cpβ1 dimers, rather than a tetramer (58). αcpβ 
appear to bind ligand reversibly based on flash photolysis and stopped-flow (SF) data (Table 4). αcpβ 
exhibits biphasic ligand binding kinetics, with a significant shift to R-state vs. T-state compared to 






Table 4. Rate constants of CO and O2 binding to HbA and αcpβ (58). 







HbA 100% photolysis 0.09 8.3 HbA 100% photolysis 7.09 59.71 


















Figure 14. Time courses for full photolysis of CO from HbA and αcpβ (panel A) and partial photolysis 
(B) of CO from HbA and αcpβ. Experiments were conducted in 0.1 M potassium phosphate, 1 mM 
EDTA, pH 7.0 at 20 oC (58). 
 
Not only does αcpβ retain similar function with reversible ligand binding to wild-
type Hb, it also possesses similar fold and structure. A crystal structure, shown in Figure 15, 
was solved for αcpβ to 2.7 Å resolution. The crystal structure confirms association of the 
four subunits with an α1/cpβ1 interface that is analogous to the wild-type α1/β1 interface. 








permutation. Additionally, the R-state Hb conformation is favored. The key conclusion from 
this study is that the circularly permuted Hb has the expected structure: The cpβ termini 
were successfully localized to the α1β1 interface, and the permutation did not significantly 
perturb the β-globin structure.      
 
Figure 15. Crystal structure of αcpβ. The blue subunits are cpβ-globin and red subunits are α-globin. 
The two light blue loops on the cpβ-globins are the locations of the inserted linker between native N- 
and C-termini. Unpublished data by Michael Murphy and Clint Spiegel.   
The next phase in the design of a single-chain Hb requires the introduction of novel covalent 
connections between the new cpβ-termini and the G-H loop in the α-subunit to create single-chain 
αcpβ (sc-αcpβ). Expression yields of this construct were greatly decreased compared to αcpβ, 
implying decreased stability (6). Three mutations in HbA (β G16A, β H116I, and α G15A) were 
discovered by Graves et al. to increase stability of apohemoglobin, add resistance to denaturation, 
and enhance expression levels in E. coli (6). In addition, the so-called “Providence” mutation, β 
K82D, was shown by Weickert et al. to enhance stability and expression yields in recombinant Hb 




resulting in increased expression yields. Subsequently, these mutations were integrated into sc-αcpβ 
(sc-αcpβ 4sm). Analytical HPSEC data supports again that these Hbs exist as a mixture of 
heterotetramers and heterodimers at μM concentrations (data not shown). To stabilize the 
tetramer structure, a glycine linker was integrated between the two α-globins (diα-cpβ). Based on 
equilibrium O2 binding data, all of these constructs appear to be high affinity (R-like) and all have 
similar ligand binding affinities (Figure 16). This implies that the novel connections in sc- αcpβ and 









Figure 16. Equilibrium binding data was collected in 100 mM potassium phosphate buffer at pH 7.0, 
1.5 mM EDTA. All samples were 30 μM in terms of heme. 
 
One-dimensional NMR studies show folding around the heme pocket for sc-αcpβ variants 




























































Figure 17. 1-D 1H NMR of wild-type and permuted Hbs. A: Oxygenated isoforms. B: Cyanomet 
isoforms. All samples obtained at 21°C in 20 mM potassium phosphate buffer, pH 7.0, 10% D2O. Data 
was collected at 500 MHz with a WATERGATE pulse sequence. Oxygenated samples show minimal 
perturbation of the heme pocket and α1β1 subunit interfaces. Unpublished data by Janette Myers and 













 Based on the encouraging results obtained with previous permuted Hb constructs, our lab 
has generated the first reported scHb. As outlined in Figure 13, the sc-Hb gene was constructed by 
linking two consecutive sc-αcpβ 4sm genes with a single glycine codon. Preliminary ligand binding 
and structural studies have been performed to assess the consequences of covalently linking the 
four subunits of Hb. This information will help to further the knowledge in the field of RBC 
substitutes, and scHb will potentially serve as a starting material or scaffold for a next generation 






















Materials and Methods 
 
Computationally designed circularly permuted myoglobin 
Gene design. The three computationally designed myoglobins were designed by Ashutosh 
Jogalekar and Brian Kuhlman using RosettaDesign software. The genes were synthesized and sent to 
us by GenScript (Piscataway, NJ) in pET-28a plasmids. 
Protein expression. Plasmids were transformed into E. coli BL 21 cells and grown at 37° C in 
Terrific Broth (TB) medium (12 g/L  tryptone, 24 g/L yeast extract, 4 mL glycerol, 2.31 g/L KH2PO4, 
and 12.54 g/L K2HPO4) with 30 μg/mL kanamycin. Using shake flasks, cells were grown to an optical 
density of 0.8-1.0 at 600 nm followed by induction with 1 mM isopropyl β-thiogalactopyranoside 
(IPTG) at 30 oC for 6 hours. Cultures were harvested by centrifugation at 5,000 x g for 10 minutes. 
The supernatant was discarded, and the cell pellet was stored at -80˚ C. 
Inclusion body preparation. All steps were performed on ice. Cells from 1-L growths were 
rapidly thawed and resuspended in 35 mL of Buffer A (50 mM Tris-HCl, 1 mM EDTA, pH 7.5 ) with 
the addition of 42 μL beta-mercaptoethanol. 10 mg lysozyme per gram of cells was added to the cell 
suspension, immediately followed by the addition of one cOmplete Protease Inhibitor Cocktail tablet 
(Roche Applied Sciences) dissolved in 2 mL ddH2O. The solution was mixed with a glass rod every 5 
minutes to avoid metal contaminants, and allowed to incubate for 30 minutes. Once the mixture 
had a thicker consistency, MgCl2 was added to a final concentration of 5 mM, immediately followed 
by the addition of 300 μL of 1 mg/mL DNase. The cell suspension was again mixed on ice for 30 
minutes. The resulting lysate was centrifuged at 30,000 x g for 15 minutes. The supernatant was 
discarded and the pellet was resuspended in 35mL of Buffer A. The suspension was sonicated on ice 




Instruments, Inc. Sonifier (model 450) equipped with a 1.8 cm diameter horn using a 50% duty cycle 
and a power output level of 5. This sonication and resuspension process was repeated two more 
times, each time discarding the supernatant. The final pellet was resuspended in 35 ml of Buffer A 
and 2.1 g of urea. This suspension was incubated for 30 minutes, followed by centrifugation at 
30,000 x g for 15 minutes.  The supernatant was discarded and the pellet was retained and stored at 
-80 oC.  
The inclusion body pellet was thawed and resuspended in 30 mL of Buffer B (10 mM 
dithiothreitol (DTT), 0.1% trifluoroacetic acid) and sonicated on ice for 5 minutes, in 1 minute 
increments with 1 minute intervals between each round, with a 50% duty cycle and a power output 
level of 7. The suspension was centrifuged at 30,000 x g for 15 minutes. The supernatant was saved 
and acetonitrile added to 10% (w/v).  The supernatant was filtered through a 0.45 μm syringe 
cassette filter (Millipore Durapore) with a fiber glass prefilter. 
The filtered solution was applied to a preparative, 22 x 250 mm, PROTO 300 (Higgins 
Analytical) C4 reversed-phase high performance liquid chromatography column at a flow rate of 2 
mL/min. The initial mobile phase was 10% MeCN/H2O. All mobile phase buffers contained 0.1% TFA. 
The sample was eluted at a flow rate of 10 mL/min, with a gradient up to 70% MeCN/H2O over the 
course of 30 minutes.  The absorbance was monitored at 280 nm and peaks were collected in 
separate fractions. These fractions were lyophilized to remove solvent and stored at -80 oC.  
Protein reconstitution. Each step of protein reconstitution was carried out at 4 oC. 
Lyophilized protein was solubilized with 5 mL of sodium acetate buffer (10 mM, pH 6.0) containing 6 
M urea. A heme dicyanide solution was prepared to provide a 1.2 molar heme excess over 
apomyoglobin. Hemin (98% +, Alfa Aesar), was dissolved in 10 mL of 10 mM sodium hydroxide 




buffer (100 mM, pH 8.0) containing 100 mM KCN, and allowed to mix for 20 minutes. A rapid 10-fold 
dilution was carried out by the addition of potassium phosphate buffer (100 mM, pH 8.0), followed 
by immediate addition of the heme dicyanide solution. This solution was allowed to stir for 
approximately 40 min.  
Concentrated holoprotein samples were applied to an Amersham Pharmacia Biotech 
Superdex 75 10/300 size exclusion column (SEC) equilibrated in 100 mM potassium phosphate 
buffer, pH 8.0, with a flow rate of 0.8 mL/min. The absorbance at 423 nm was monitored and 
fractions corresponding to peaks at this absorbance were collected. 
15% SDS-PAGE. Samples were prepared by the addition of 2x SDS-PAGE protein loading 
buffer (50mM Tris-HCL, 2% SDS, 0.2 % bromophenol blue, 10% glycerol, pH 6.8) and 1 μL of 1 M DTT, 
and incubated for five minutes at 100 oC. Once polymerization of the 15% (w/v) SDS-PAGE resolving 
layer was complete, the 10 % (w/v) SDS-PAGE stacking layer was added. The protein samples along 
with a protein ladder of known molecular weight standards were loaded and placed in the 
electrophoresis apparatus with Tris-glycine reservoir buffer (25 mM Tris, 250 mM glycine, 0.1% 
(w/v) SDS, pH 8.3). The gel was then subjected to 60 V through the stacking layer and increased to 
120 V at the beginning of the resolving layer until the tracking dye reached the bottom of the gel. 
After electrophoresis, gels were stained overnight with Coomassie Brilliant Blue solution (50% (v/v) 
methanol, 10% (v/v) acetic acid, 0.1% (w/v) Coomassie Brilliant Blue R250). After staining was 
completed, the gels were destained with a 1:3:4 glacial acetic acid:methanol:water solution.  
UV-Visible spectroscopy. Data was collected on a Hewlett Packard 8452A diode array 
spectrophotometer. Samples were placed in a 400 μL quartz cuvette with a 1 cm path length. Apo 
protein concentrations were estimated using Ԑ280= 15,200 M-1cm-1.  Holo cyanomet protein 




Electrospray Ionization Mass Spectrometry (ESI-MS). Purified proteins were analyzed by 
electrospray ionization mass spectrometry (ESI-MS) with an Applied Biosystems 2000 API 2000 
LC/MS/MS mass spectrometer. Samples were in either a 1:1 ratio of acetonitrile (0.1% formic acid) 
to water (0.1% formic acid) at a heme concentration between 10-20 µM. The total sample volume 
was 500 µL. Acetonitrile aided in the solubilization of the samples while the formic acid served as 
the proton source for ionization. Mass to charge ratios were obtained, averaged, and used to 
reconstruct the peptide masses.  
 
Single-chain hemoglobin 
Polymerase chain reaction (PCR). sc-αcpβ plasmids were isolated from BL21 (DE3) E. coli 
cells to be used for the cloning of scHb. Four sets of primers were ordered from Integrated DNA 
Technologies (San Diego, CA) in order to attempt the insertion of two distinct linkers between the 
termini of the α-globins. The first two sets of primers were designed to amplify the 5’ end of the 
scHb gene and the 3’ end of the scHb gene utilizing the KasI restriction site to insert a linker that 






The second two sets of primers were designed to amplify the 5’ end and the 3’ end of the scHb gene 









A Stratagene Robocycler equipped with a hot top was used to perform all PCR amplification 
reactions. Each reaction consisted of 1x Crimson Taq reaction buffer (12.5mM Tricine, 42.5 mM KCl, 
1.5 mM MgCl2, 6% Dextran, pH 8.5 at 25 oC, supplied by New England Biolabs), 50 pmol of each 
primer, 50 ng of template DNA, 10 pmol of each dNTP, and two units of Crimson Taq DNA 
Polymerase (New England Biolabs) in a final volume of 50 μL. The temperature program consisted of 
35 cycles of melting at 95 oC for 30 seconds, annealing at 55 oC for 30 seconds, followed by 90 
seconds of primer extension at 68 oC.  
DNA visualization. DNA was analyzed by gel electrophoresis on 1% (w/v) agarose gels 
containing 1X Gel Red Nucleic Acid Stain (Biotium, Inc.). Samples were electrophoresed at 200 V in a 
1x sodium borate buffer, pH 8.2 for 45-60 minutes. Samples were combined with a 1x loading buffer 
(0.04% (w/v) bromophenol blue, 0.04% (w/v) xylene cyanol, 5% (v/v) glycerol) and run alongside 10 
μL of Hi-Lo Marker (Minnesota Molecular) for approximate molecular weight determination. The 
DNA was then visualized using a UV transilluminator and documented using a digital camera. 
DNA purification. DNA was purified from PCR reactions using a QIAGEN MiniElute PCR 
Purification Kit as per the manufacturer’s instructions. DNA from restriction digests was purified 
using a QIAGEN MiniElute Reaction Cleanup Kit. Plasmid DNA was purified from overnight cultures 
of E. coli using a QIAGEN QIAprep Spin Miniprep Kit.  
Restriction digestions. All restriction digests were performed using restriction endonucleases 
supplied by New England Biolabs in the supplied buffer. Bovine serum albumin (BSA) was added to 




were performed at 37 oC for 30 minutes. 20 units of each enzyme were used in each reaction. The 
total reaction volume for each digest was 20 μL.  
Ligation. Ligation reactions were performed in 1X T4 DNA ligase buffer (50 mM Tris-HCl, 10 
mM MgCl2, 10 mM dithiothreitol, 1 mM ATP, 50 μg/mL BSA, pH 7.8 at 25 oC, supplied by New 
England Biolabs). Relative concentrations of reactants were estimated by visualization of bands on 
agarose gels prior to ligation. The reactants were then added to the reaction mixture in an 
approximately 1:1 ratio. Four hundred units of T4 DNA ligase (supplied by New England Biolabs) 
were added and the reaction mixture was incubated for approximately 16 hours at 16 oC. 
Gene design. Attempts to clone the scHb gene proved to be unsuccessful. A novel scHb gene 
was designed with a single glycine residue between the α-globins. This gene was synthesized, and 
subcloned into a custom recombinant Hb expression vector (described in ref. 58) by GenScript 
(Piscataway, NJ).     
Preparation of electrocompetent cells. One L of LB broth (10 g/L Bacto-tryptone, 5 g/L yeast 
extract, 170 mM NaCl, pH 7.0) was inoculated with a 10 mL overnight culture of BL21 (DE3) cells (F-, 
ompT, hsdSB(rB-, mB-), dcm, gal, λ(DE3)) and incubated with 175-200 rpm shaking at 37 oC until OD600 
= 0.5-0.7 was reached. The cells were then harvested by centrifugation at 4,000 x g for 10 minutes. 
The supernatant was discarded and the cells were centrifuged again briefly to remove any remaining 
supernatant. The cells were gently resuspended in 1 L of ice-cold dd H2O and centrifuged at 4,000 x 
g for ten minutes. The supernatant was discarded and the cells were resuspended in 0.5 L of ice-cold 
dd H2O. The cells were again centrifuged at 4,000 x g for ten minutes and the supernatant discarded. 
Cells were then resuspended in 20 mL of sterile, ice-cold 10% (v/v) glycerol in dd H2O and 
centrifuged at 4,000 x g. The supernatant was discarded and the cells were resuspended in 2-3 mL 




chilled microcentrifuge tubes using pre-chilled pipette tips. Cells were flash-frozen on liquid N2 and 
stored at -80 oC. 
Transformation by electroporation. E. coli cells were transformed using a Biorad Gene Pulser 
II set to a resistance of 200 Ohms, a potential of 1.25 kV/mm, and a capacitance of 25 μF. Fifty μL of 
electrocompetent BL21 (DE3) cells were added to 2 μL of either a ligation mixture or purified 
plasmid DNA (50-100 ng/μL) in a 1 mm gap cuvette and gently mixed. The mixture was then 
incubated on ice for 15 minutes. Cells were bathed in 1 mL of SOC medium (0.5% (w/v) yeast 
extract, 2% (w/v) Tryptone, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4, 20 mM glucose) 
immediately following electrical discharge, transferred to a culture tube, and incubated for one hour 
at 37 oC with ~175 rpm shaking. Several dilutions of the culture were then plated on LB-agar plates 
containing 25 μg/mL tetracycline and incubated at 37 oC for approximately 16 hours.  
 Protein expression. scHb was expressed in 1-L bacterial cell cultures (BL21 (DE3)). Overnight 
cell cultures (incubated 14-16 hours at 37 oC) were used to inoculate 1-L of TB medium containing 5 
μg/mL tetracycline in 2.8 L Fernbach flasks. The cultures were incubated at 37 oC with 200 rpm 
shaking in a Lab Line incubator-shaker. The cells were grown until an OD600 of 2.0-2.2 and induced 
with 1 mM isopropylthiogalactoside (IPTG). Heme solution was prepared by dissolving 0.05 g of 
hemin per liter of culture in 5 mL (per 0.05 g) of 20 mM NaOH and then filtering with a sterile 0.2 μm 
disposable cellulose acetate membrane syringe filter (VWR International). 1 mL of the hemin 
solution was added to each culture every hour. The cultures incubated for 5 hours at 30 oC and 
harvested by centrifugation at 5,000 x g for 10 minutes. The cell pellet was resuspended in ~35 mL 
lysis buffer (17 mM NaCl, 50 mM Tris-HCl, pH 8.5) and stored at -80 oC.  
Protein purification. Resuspended cell pellets were thawed and then lysed by sonication for 




horn using a 50% duty cycle and a power output level of 6. The crude lysate was centrifuged at 
21,000 x g for 20 minutes. The pH of the supernatant was adjusted to 8.0-8.5 and zinc acetate from 
a 0.5 M stock was added to a final concentration of 4 mM. The lysate was centrifuged again at 
40,000 x g for 20 minutes and filtered in a Millipore cassette with a glass prefilter, then filtered with 
a 0.45 µM SFCA bottle top vacuum filter (Fischer Scientific).  
Immobilized metal ion affinity chromatography (IMAC). The clarified cell lysates were IMAC 
purified using a 10 mL column of Amersham Pharmacia Biotech Chelating Sepharose Fast Flow resin. 
The flow rate was 3 mL/min. The column was prepared for loading of clarified lysate as follows: 4 
column volumes (CV) of 0.2 M NaCl, 2 CV of 20 mM Zn(OAc)2, and 6 CV of 0.2 M NaCl. The clarified 
lysate was then loaded and the column was washed as follows: 8 CV of 20 mM Tris-HCl, 0.5 M NaCl, 
pH 8.5; 2 CV of 250 mM Tris-HCl, pH 8.5; and 6 CV of 20 mM Tris-HCl, pH 8.5. The flow rate was then 
slowed to 2 mL/min and the protein eluted with 20 mM Tris-HCl, 15 mM EDTA, pH 8.5. A total of 10-
15 mL of purified protein was collected and then buffer exchanged into 20 mM Tris-HCl, pH 8.5 by 
centrifuging in 15 mL Amicon Ultra concentrators with a molecular weight cut-off of 10 kDa at 4,000 
x g for 10-12 minutes. The protein sample was exchanged 6 times into 20 mM Tris-HCl and stored at 
4 oC. 
Ion exchange chromatography. Proteins were purified by quaternary amine anion exchange 
chromatography using an Amersham Biosciences Mono Q 10/100 GL column (8 mL volume). The 
flow rate was 2 mL/min. Protein samples were prepared for loading onto the column by filtering 
through a 0.22 μM Cellulose Acetate Spin-X centrifuge tube filter (Costar) at 13,000 rpm for 1 
minute. The column was prepared as follows: 5 CV of dd H2O; 5 CV of buffer A (20 mM Tris-HCl, pH 




A volume of 500 µL of the IMAC-purified protein sample was then loaded and eluted with an 80 
minute gradient to 100% buffer B at a flow-rate of 2 mL/min.   
The absorbance of the eluent was monitored at 280 nm and fractions with significant 
absorbance were collected and analyzed by SDS-PAGE. Protein samples typically eluted when the 
buffer composition reached 25% B. Samples were then concentrated to a volume of 500 μL. 
High pressure size-exclusion chromatography (HPSEC). Filtered protein samples post Mono 
Q were purified by HPSEC using an Amersham Pharmacia Biotech Superdex 75 size exclusion column 
(24 mL volume connected to an Åkta Purifier FPLC system (GE HealthSciences). The flow rate was 0.8 
mL/min. The column was prepared for loading of protein by washing with 2-3 CV of buffer (for 
buffer composition, see the respective protein characterization experiments). All buffers were 
filtered before use with Millipore 0.45 µM filters. A sample volume of 300-500 µL was injected and 
the absorbance monitored at 280 nm. All peaks with significant absorbance at 280 nm were 
collected and concentrated as described above in the IMAC purification section.  
 Protein characterization. scHb was characterized by SDS-PAGE, UV-Visible spectroscopy, and 
electrospray ionization mass spectrometry (ESI-MS) to determine purity, concentration, and size. For 
methods, see sections described above for computationally designed myoglobins.   
Analytical HP-SEC. Analytical size exclusion chromatography was performed using the same 
column as described in the HPSEC purification section connected to a Varian ProStar automated 
HPLC system. The retention times based on the absorbance at 414 nm were recorded by the 
manufacturer’s software package. Experiments were performed using a 20 mM potassium 
phosphate buffer, pH 7.0 at a flow rate of 0.5 mL/min. Protein samples were concentrated to 160 




Nuclear magnetic resonance. 1H NMR spectra of the scHb and rHb0.0 were obtained at 25°C 
for oxy isoforms. NMR samples consisted of unlabeled recombinant proteins between 0.5-1 mM in 
heme concentration in 20 mM potassium phosphate buffer at pH 7.0 in 10% D2O. All data were 
collected on a Varian Inova Unity spectrometer operating at 11.75 T (500 MHz) field strength with a 
Varian high-field triple resonance 500 TR/PFG TRIAX probe. Water suppression was achieved with a 
Presat pulse sequence. 
 Ligand binding studies. Ligand binding studies were performed in the laboratory of Professor 
John Olson at Rice University. The HbA samples used in the studies were provided by Dr. Olson. The 
buffer used in all ligand binding experiments was 100 mM potassium phosphate, 1 mM EDTA, pH 
7.0. Anaerobic buffer was prepared by putting 20-30 mL of buffer in a gas-tight syringe and 
dispelling any air bubbles. The syringe was stoppered and then bubbled with a steady stream of 
100% CO or 5% (v/v) CO in N2 for 30 minutes.  
Laser flash photolysis. For laser flash photolysis of samples in 100% CO, stoppered, 1 mm 
path length quartz cuvettes containing a few grains of sodium dithionite were purged with CO for 
five to ten minutes. Samples were prepared to a final concentration of ~50 µM in heme in a final 
volume of 500 µL using gas-tight Hamilton syringes. The syringe was rinsed several times with water 
to remove any air bubbles and then rinsed with 100% CO buffer three times. Buffer was then 
dispensed into the stoppered cuvette, followed by the corresponding amount of protein. UV-Vis 
spectra were taken to determine the final heme concentrations. The 100% CO samples were 
incubated in a 20 oC water bath for approximately ten minutes and then kept on ice. 
Photolysis experiments were conducted using the method described by Rohlfs et al. (57). 
Briefly, ligand was dissociated using a ~0.3 µsecond pulse from a Phase-R Model 2100B dye laser 




photomultiplier tube attached to an oscilloscope and the resulting signal was then digitized using an 
A/D converter and transferred to a personal computer, where it was then converted to absorbance 
data. For partial photolysis, the intensity of the laser pulse was attenuated by placing neutral density 
optical filters in front of the laser beam. The percent photolysis was then calculated by taking the 
amplitude in absorbance change for partial photolysis as a percentage of the amplitude in 
absorbance change for full photolysis. Single and double exponential decay fits were performed on 
the raw data for partial and full photolysis, respectively (with the data prior to t = 0 sec removed) 
using either Origin 8.5 or Igor Pro to obtain the observed rates for ligand recombination (kobs). 
Pseudo first order rate constants were calculated by dividing the observed rates by the 
ligand concentration (928 µM for CO). The rate constants for association to the R state, k’R were 
calculated from both full and partial photolysis data, while the rate constants for association to the T 
state, k’T, were determined from the full photolysis data.  
Stopped flow. Stopped flow experiments were conducted at 20 oC using a Gibson-Dionex 
stopped flow apparatus with the OLIS model 3820 data collection system described by Rohlfs et al. 
(57). For the measurement of O2 off-rates by displacement with CO, 4 µM Hb (in heme) samples 
were prepared in a final volume of 3 mL. Samples were rapidly mixed with an equal volume 100% 
CO buffer containing sodium dithionite to remove the displaced O2 and the absorbance change at 
424 nm was monitored. The final concentrations of CO and O2 after mixing were 464 µM and 131 
µM, respectively. Single exponential decay fits were performed on the raw data using Origin 8.5 to 
obtain robs, the observed rate for replacement of O2 by CO.  
For measurement of the rate of CO binding to deoxy HbA, αcpβ, sc-αcpβ, and scHb, samples 
were prepared to the same heme concentrations and final volumes as listed above in N2-




of buffer containing 5% (v/v) in N2 to a final concentration of either 23 µM or 93 µM CO. The 
absorbance change at 436 nm was monitored and the raw data fit with a single exponential decay 
using Origin 8.5 to obtain kobs. The pseudo first order rate constant for CO binding to the T state, k’T, 
was then calculated by dividing kobs by the final concentration of CO. 
Oxygen equilibrium curves. Oxygen equilibrium curves (OEC) were collected using a HEMOX 
apparatus. The absorbance at 430 nm was monitored at 20 oC as the partial pressure of oxygen was 
increased. The first derivatives of the OEC curves were then calculated using Origin 8.5. The OEC 
curve fitting was determined using an excel spreadsheet provided by Professor Olson. Based on the 




















Computationally designed circularly permuted myoglobin 
Protein expression. The permuted model proteins were expressed in BL21 (DE3) E. coli cells. 
To determine whether or not the model proteins could be expressed in E. coli, several test 
expressions were performed to determine soluble and insoluble expression using SDS-PAGE. Over-
expressed bands were present in the insoluble fractions for ML1 and ML2 (Figure 19). These 
expression studies indicated that the model proteins were likely forming inclusion bodies. Inclusion 
body yields for ML1 were determined post HPLC purification and were typically found to be 2.5-3 
mgs of protein per liter of culture. After reconstitution and final purification over SEC, the final yield 







Figure 19. Analysis of test expression by 15% SDS-PAGE. Red circles indicate bands of the expected 
MW for the desired protein. 
 
Protein purification and reconstitution. ML1 was purified using an inclusion body 
preparation, followed by a two-column purification procedure and reconstitution to the fully-folded 
cyanomet isoform. Compared to the HPLC elution profile of wild-type Mb and HGL16, ML1 had a 




residues in the permutein linker (data not shown). Unlike wild-type Mb and HGL16, ML1 eluted as 
two distinct peaks (peak 2A and peak 2B, Figure 20B). These peaks were collected and reconstituted 
separately. Analysis by SDS-PAGE revealed peaks 2A and 2B both appeared to have the expected 









Figure 20. A: 15% SDS-PAGE analysis of ML1 elution from C4 reversed-phase column (lanes 1 and 2), 
ladder (lane  3), and analysis of purity post SEC (lane 4). B: Typical HPLC elution profile of ML1 from a 
C4 reversed-phase column using an acetonitrile gradient. Peaks 2A and 2B are the desired permutein.   
 
Optimized reconstitution conditions were determined based on the final percent recovery 
of folded protein. The conditions that resulted in the greatest protein recovery consisted of a rapid 
10-fold dilution with a 100 mM potassium phosphate buffer pH 8.0 and an addition of 1.2 mol 
excess of cyanomet heme. Several other conditions were tested, but most caused substantial 
protein aggregation. Systematic variation of the three sets of conditions described below led to the 

















































potassium phosphate buffer of denatured protein dissolved in 6 M urea buffer followed by 
immediate addition of cyanide buffer with 1.2X mol excess hemin to protein (pH 7.5). Attempts at 
varying concentrations of cyanide, volumes added for dilution, and pH at 8.0 failed. Second, slow 
dilution of denatured protein in 6 M urea and cyanide buffer with 1.2X mol excess hemin using 
dialysis in 1-L dialysis buffer (50 mM potassium phosphate pH 7.5). Third, a wider scan of conditions 
was utilized to find optimal refolding conditions using several additives (the starting concentration 
of protein was 0.5 mg/mL). Each individual additive was incorporated in a slow drop-wise manner 
into 50 mM or 100 mM potassium phosphate buffer pH 8.0 with diluted protein. The additives 
included: 10% and 20% glycerol; 0.5 M, 1.0 M, and 1.5 M trimethylamine N-oxide dihydrate; 40 μM 
PEG 3350; 400 mM L-Arginine; and 10 mM DTT. Most of these approaches resulted in significant 
aggregation, except for 100 mM potassium phosphate in the absence of an additive, and 100 mM 
potassium phosphate with glycerol, PEG, or arginine. Proper folding of the permuted myoglobin 
under these conditions was assessed using UV-Vis spectrometry. The typical UV-Vis absorbance 
spectrum of a wild-type cyanomet Mb possesses a Soret band with a λmax at 423 nm and a smaller 
peak at 538 nm. This characteristic spectrum was used as a reference to determine whether ML1 
was correctly folded around the heme pocket. Each of the samples obtained from refolding 
conditions that showed little to no aggregation had a λmax less than 423 nm. This indicated that the 
resulting proteins were not correctly folded around the heme pocket. 
Several unsuccessful attempts were made to drive ML1 into soluble expression. The first 
effort varied the OD600 at which cells were induced, from ~ 0.6 to ~ 1.5, as this OD600 had been 
shown to yield greater expression of soluble permuted Hb in our lab. Insertion of the heme uptake 
gene (HUG) cassette into the ML1 expression plasmid also did not yield soluble protein. 




(59), presumably due to increased heme transport from the growth medium into the cell, which 
should favor folding of the apo-protein vs. aggregation into inclusion bodies.  
Protein characterization. The expected mass of the purified ML1 protein was verified by ESI-
MS (Table 5). The two peaks from HPLC were analyzed by ESI-MS separately to determine whether 
there was a mass difference between them. The observed mass of peak 2A was consistent with the 
expected mass of ML1, but the mass of peak 2B was approximately 30 Da heavier. The observed 
mass difference for peak 2B may be a result of post translational modification by methylation (60). 
This observation can be supported by the protein’s C4 reversed-phase elution: the retention time of 
2B is slightly longer than 2A, which would be consistent with the presence of additional methyl 
groups that increase hydrophobic interactions with the C4 column.  
Table 5. Mass determination of ML1 by 
ESI-MS. 
 Molecular weight (Da) 
Expected mass 19,373 
ML1 (Peak 2A) 19,377 
ML1 (Peak 2B) 19,408 
 
Using the previously described optimal reconstitution conditions, folded protein from peaks 
2A and 2B both possessed a UV-Vis spectrum identical to that of cyanomet wild-type Mb and HGL16 
in the Soret region (Figure 21), suggesting that both peaks were ML1. Subsequently, the peaks were 
collected and reconstituted together as a single sample. The increased absorbance at 280 nm for 
ML1 compared to wild-type Mb and HGL16 is consistent with the presence of additional aromatic 














Figure 21. UV-Visible spectra of wild-type Mb, HGL16, and ML1 are identical in the Soret region, 
indicating ML1 has a similar fold around the heme pocket compared to wild-type Mb. Spectra of 
proteins were recorded in 100 mM potassium phosphate buffer, pH 8.0.    
Single-chain hemoglobin 
Gene construction. PCR-based cloning strategies were initially employed to construct the 
scHb gene by insertion of a linker sequence between the α-subunits of two sc-αcpβ genes. The 
linker must meet the following design constraints: it can only be one to three residues in length; it 
must code for small, polar residues; and the restriction sites must be unique in the gene to allow 
assembly of PCR-amplified fragments. The two linker sequences that meet each of these 
requirements include the following: 
(1) KasI (G^GCGC_C)  gly-ala 
(2) SalI GG(G^TCGA_C)C  gly-ser-thr 
Each of these recognition sites codes for short sequences containing small, polar residues. On its 
own, the SalI restriction site codes for Val-Asp residues, so codons were inserted out of frame to 
create a more suitable linker sequence. PCR primers were designed with either the KasI or SalI on 






























the 5’ ends. These primers were used in PCR reactions to amplify the sc-αcpβ genes with the 
addition of the incorporated restriction sites to create products that could be ligated to form the 
scHb gene fragment. Once this gene fragment was formed, the scHb DNA would be ligated into the 
vector used previously to express αcpβ in E. coli (58, Figure 22). 
Figure 22. Scheme for cloning scHb gene fragment into an appropriate expression vector. 
 
When this process was attempted with primers for the KasI restriction site, a small quantity 
of ligated product was observed after the digestion with KasI and ligation with T4 ligase. However, 
no amplification of the ligated scHb gene was observed (Figure 23). Amplification of the DNA 
fragments with the SalI primer set yielded only the 3’ half of the gene. Following several failed 
attempts to clone the scHb gene, a novel scHb gene was designed with a single glycine residue 












Figure 23. Lanes listed from left to right: HI-LO ladder (lane 1), PCR product from amplification of 
ligation (lane 2), ligation product (lane 3), PCR product amplifying 5’ end of scHb gene (lane 4), and 
PCR product amplifying 3’ end of scHb gene (lane 5). 
 
Protein expression and purification. Single-chain Hb was expressed in BL21 (DE3) cells. The 
protein expressed in the soluble fraction and was purified to ≥ 95% homogeneity using a three-
column protocol (Figure 24). Expression yields were determined post IMAC and typically ranged 
from 0.4-0.6 mgs per liter of culture. After the final SEC purification step, the percent recovery of 












Protein characterization. The expected mass of scHb was verified by ESI-MS (Table 6). The 32 
Da increase in the observed mass may either be due to di-methylation (60) or oxidation of a cysteine 
residue to cysteic acid, or methionine to the sulfone. The cyanomet isoform of Hb has a 
characteristic spectrum in the Soret region with a λmax at 418 nm and an additional peak at 541 nm. 
The UV-Vis spectra for wild-type Hb and scHb (in their cyanomet isoforms) are identical in the Soret 
region and provide evidence that the heme pocket is unperturbed in (Figure 25). 
Table 6. Mass determination of scHb by 
ESI-MS. 
 Molecular weight (Da) 
Expected mass 64,404 









Figure 25. Preliminary UV-Visible spectra of wild-type Hb and scHb. A wild-type spectrum must be 
obtained from a sample of increased purity for more conclusive evidence, however the high similarity 
between the Soret peaks at 418 and 541 nm indicates that the heme pocket of scHb has not been 





Based on data obtained by analytical HPSEC, scHb forms a tetramer in oxygenated 
conditions. Shown in Figure 26, the retention time of scHb (18.9 min) corresponds to that of wild-
type Hb (19.1 min). Furthermore, the elution profile of wild-type Hb possesses a shoulder at 
approximately 21.2 min due to a small formation of α1β1 dimers. There is no evidence of a shoulder 










Figure 26. Comparison of scHb (blue) and wild-type Hb (red) elution profiles off of analytical HPSEC 
monitored at 414 nm. Both samples were prepared in 20 mM potassium phosphate, pH 7.0.  
 
Nuclear magnetic resonance (NMR). Analysis of oxy-scHb by 1H NMR indicates that the 
heme pocket environment and α1β1 subunit interfaces of wild-type Hb and sc-Hb are similar (Figure 
27). Both spectra show shifts at 12.1 and 12.9 ppm which arise from NεH resonances of α103His and 
α122His side chains (61,62). These two His side-chains are located at the α1β1 interface and contact 
β131N and β35Y, respectively. The α1β2 interface was monitored by a characteristic R-state marker 




side chain is located within the hinge region of the α1β2 interface, and forms an H-bond with α94D 
early in the R-to-T transition (63). In the upfield region, there is a discernible peak in both spectra at 
-2.5 ppm, as expected from ring-current shifted α62V and β67V methyl resonances. The distal valine 
side-chains are located within 4 Å of the bound O2, and provide useful markers to track the heme-
pocket environment (61). This evidence implies that the incorporated linkers and mutations do not 














Figure 27. 1H NMR spectra of oxy scHb (stacked on top for both images) and oxy wild-type Hb 
(stacked on bottom for both images). Top: Comparison of full spectra from 15 to -5 ppm. Bottom: 
Downfield and upfield spectra with a higher scaled image, highlighting shifted resonances previously 




Ligand binding. Full photolysis studies of CO-bound HbA and permuted Hb constructs 
developed in our lab were used to estimate the pseudo first-order rate constant, k’T, for ligand 
recombination to the low-affinity T conformation. Partial photolysis was employed on the same Hb 
constructs to determine the pseudo-first-order rate constant, k’R, for ligand recombination to the 
high affinity R conformation. According to a four-step ligand association process, k’R is defined as the 
final step in ligand binding (i.e., Hb4X3 + X) (64). Binding isotherms for full and partial photolysis of 
CO from HbA and Hb constructs are shown in Figure 28. In full photolysis experiments, each protein 
displays biphasic kinetics. The fast phase coincides with ligand rebinding to the R state 
conformation, and the slow phase with rebinding of ligand to the T state. The apparent rates 
depend on ligand concentration, which is used to calculate bimolecular association rate constants R 
and T states (Table 7). In each of the permutants (αcpβ, sc- αcpβ, and scHb), ligand binding is 
dominated by the fast phase. In contrast, HbA possesses dominant amplitude in the slow phase. This 
disparity may be a result of either (1) a presence of higher concentration of heterodimers, or (2) a 










Figure 28. Normalized time courses for full photolysis of 1 atm CO from HbA, αcpβ, sc-αcpβ, and scHb 
(panel A), and approximately 10% partial photolysis of 1 atm CO from HbA and scHb (panel C). Time 
courses for full photolysis of 92.8 μM CO from HbA, αcpβ, sc-αcpβ, and scHb (panel B) and about 10% 
photolysis of 92.8 μM CO from scHb and αcpβ 6 MT (panel D). No new data for HbA at 10% photolysis 
with 92.8 μM CO was obtained, but based on previous data, αcpβ and mutants have nearly identical 
time courses to HbA. By extrapolation, scHb likely has similar time courses to HbA under these 
conditions. All experiments were conducted in CO-saturated 0.1 M potassium phosphate and 1 mM 
EDTA, pH 7.0 at 20 oC.  
  
 In the first scenario, the newly formed deoxy heterodimers remain in a highly reactive R 
conformation and will likely rebind CO before the deoxy-heterodimers can associate into 
heterotetramers and switch to a T-state conformation. For HbA, the rate of CO binding is relatively 
quicker than the rate of heterodimer aggregation (k’2,4 ≈ 0.1 μM-1s-1) (64). In the second scenario, a 
destabilized T conformation would result in a lower population of the T state. Therefore, the highly 
reactive R-state conformation would dominate the population of deoxy-Hb molecules and result in a 




may have a role in the observation of a dominant fast phase. However, analytical SEC shows that 
scHb exists as a tetramer (Figure 26), so it is more likely that a dominant fast phase is a result of a 
destabilized T-state for this particular mutant.  
Table 7. Second-order rate constants for the faster and slower phases of CO 
binding to HbA and Hb mutants. 
CO binding k’T(CO) (μM-1s-1) k'R(CO) (μM-1s-1) 
HbA*  0.12 6.0 
HbA 100% photolysis 1 atm CO 0.19 (72) 9.12 (28) 
HbA 100% photolysis 10% CO .061 (74) 3.11 (26) 
HbA ~10% photolysis  4.79 
deoxy HbA + 23 μM CO 0.10  
deoxy HbA + 93 μM CO 0.075   
αcpβ 100% photolysis 1 atm CO 0.56 (25) 6.80 (75) 
αcpβ 100% photolysis 10% CO 0.21 (31) 3.91 (69) 
αcpβ ~10% photolysis  6.54 
deoxy αcpβ + 23 μM CO 0.28  
deoxy αcpβ + 93 μM CO 0.25   
sc-αcpβ 100% photolysis 1 atm CO 1.02 (22) 10.08 (78) 
sc-αcpβ 100% photolysis 10% CO 0.29 (27) 4.52 (73) 
sc-αcpβ ~10% photolysis  9.10 
deoxy sc-αcpβ + 23 μM CO 0.33  
deoxy sc-αcpβ + 93 μM CO 0.36   
scHb 100% photolysis 1 atm CO 1.0 (35) 9.10 (65) 
scHb 100% photolysis 10% CO 0.26 (46)  -  
scHb ~10% photolysis  8.97 
deoxy scHb + 23 μM CO 0.47  
deoxy scHb + 93 μM CO 0.30   
The amplitudes of fast R state and slow T state phases are given in parentheses. 
The CO binding values were calculated from full and partial photolysis, as well as 
stopped-flow experiments. *HbA values are from Olson et al. (64)  
 
The published value for k’R for CO binding to HbA (6.0 μM-1s-1, 64) and measured value for 
scHb (8.97 μM-1s-1) are not significantly different (Table 7). This implies that the proteins have similar 
R-states and reactivities. Although we have not distinguished differences between α and β subunits, 




HbA (less than 2-fold) (64). Unzai et al. have argued that although the structural mechanisms for 
ligand binding in the two subunits are significantly different, they have evolved with similar rates 
and equilibrium constants in order to maximize observed cooperativity (65). Thus, simple 
parameters assuming subunit equivalence are sufficient to simulate O2 transport properties of Hb. 
Because the time courses for partial photolysis are similar between HbA and permuted Hb 
constructs, neither subunit has been particularly disturbed by the added linkers. Otherwise, 
multiphasic time courses would have been observed for the mutants.    
The apparent O2 dissociation rates were determined using stopped-flow by mixing HbO2 
with solutions containing excess CO and measuring the displacement of O2 (Figure 29). The apparent 
rates for HbA and αcpβ are essentially identical, and rates for sc-αcpβ and scHb are slightly lower, 
but not significantly different (Table 8). Therefore, O2 dissociation is very similar between the 









Table 8. Apparent dissociation rates for 
O2 displacement of Hb by CO   
  Apparent kR(O2) (s-1) 
HbA 8.0 
rHb 0.1 6.5 
αcpβ  8.2 
sc-αcpβ  4.9 




Figure 29. Normalized time courses for stopped-flow measurement of CO binding to deoxyHbA, 
deoxy αcpβ, deoxy sc-αcpβ, and deoxy scHb (panels A and B). Panel A shows data collected in the 
presence of 23.2 μM CO and panel B shows data collected in the presence of 92.8 μM CO. Panel C 
shows normalized time courses for O2 displacement of HbO2 by excess CO. Samples were prepared in 
0.1 M potassium phosphate and 1 mM EDTA, pH 7.0, and data collected at 20 oC.          
 
Although the R state ligand binding parameters are similar between HbA and mutants, 
values of k’T for the slow phases of ligand rebinding to Hb vary significantly from HbA values. In full 
photolysis experiments, k’T values are 3-8 fold higher than for HbA (Table 7), indicating the iron in 
Hb mutants has higher reactivity in the deoxy state. Additionally, the amplitude for the slow T-state 
is much lower in Hb mutants compared to HbA (Table 7). These rates were confirmed by stopped-
flow methods by mixing deoxy Hb with either 10% or 2.5% CO and monitoring absorbance at 436 




acceleration at the start of the reaction with an overall bimolecular rate constant of ~0.10 μM-1s-1 
for reaction with 2.5% CO and ~0.075 μM-1s-1 for reaction with 10% CO. In contrast, each of the 
mutants displays a simpler exponential process. The single rapid rate derived from reaction with 
scHb is ~0.47 μM-1s-1 and ~0.30 μM-1s-1 for reaction with 2.5% CO and 10% CO, respectively. For each 
of the mutants, a considerably smaller k’T association rate constant is observed compared to rates 
measured after partial photolysis. This implies that the mutants form a T state tetramer, but one 
with higher affinity compared to HbA. This conclusion is supported by equilibrium oxygen binding 
curves shown in Figure 30. Each of the mutants (sc-αcpβ and scHb) display lower P50 values and 
significant less cooperativity compared to HbA (Table 9).   
 
Figure 30. Fractional saturation with oxygen versus log of oxygen partial pressure (mm Hg) for HbA, 
fetal Hb (HbF), sc-αcpβ, and scHb. Samples were prepared in 0.1 M potassium phosphate and 1 mM 





Table 9. Partial pressure and 
cooperativity constants for equilibrium 
oxygen binding 
  n Hill P50 (mm Hg) 
HbF 1.74 8.69 
HbA 2.0-2.1 13.2-13.8 
sc-αcpβ 1.1-1.2 10.8-11.9 




















Computationally designed circularly permuted myoglobin 
Computational protein design provides a potentially useful tool for the construction of novel 
sequences and interactions. Previous investigations by Hu et al. have determined that it is possible 
to design a 10-residue loop with high accuracy using the current Rosetta energy function (46). For 
the first time using similar methods on Rosetta software, three circularly permuted sperm whale Mb 
designs were created. Each of these designs was modeled to contain an α-helical linker between the 
native N- and C-termini designed to include novel hydrophobic interactions with the Mb framework. 
 Attempts to express these models resulted in the formation of inclusion bodies with no 
evidence of soluble expression. This result is in contrast to the previously characterized permutein, 
HGL16, which had isolated yields of 0.6-1.2 mg soluble protein/L of fermentation broth. The absence 
of soluble expression for the computationally designed permuteins is probably due to a decreased 
thermodynamic stability (66). For swMb and HbA, it has been shown that decreased thermodynamic 
stability correlates with a decreased expression yield (6,68). Additionally, reconstitution of ML1 
inclusion bodies proved to be more challenging compared to reconstitution of HGL16 from inclusion 
bodies (67). ML1 was more prone to aggregation during the refolding process than HGL16 and had a 
decreased recovery yield of fully folded protein, supporting the notion that ML1 has a reduced 
thermodynamic stability compared to HGL16.  
 UV-visible spectra shown in Figure 21 indicate that ML1 has the correct fold around the 
heme pocket. Further characterization of the computationally designed permuteins must be 
completed to quantify the loss of thermodynamic stability. Given the data collected so far, it does 




permuted β-globin of scHb. However, it would be interesting to determine how accurately the 
computational design predicted the fold of the reconstituted permutein in order to validate the 
computational design algorithm.  
 
Single-chain hemoglobin 
 Prior to the generation of scHb according to the scheme illustrated in Figure 13, two Hb 
constructs had to be produced and characterized as a proof of concept that Hb can tolerate the 
permutations and novel covalent linkages required by the scheme. The first proof of concept came 
from αcpβ, which had a similar fold and function to HbA in the R conformation. A similar conclusion 
was reached with sc-αcpβ, although each mutant became progressively more destabilized. Prior 
results show αcpβ and sc-αcpβ have R-state ligand binding and dissociation properties that are very 
similar to the R-state properties of wild-type Hb. However, unlike HbA, the faster phase of binding is 
dominant over the slower phase. This is evidence that the R ↔ T equilibrium for both αcpβ and sc-
αcpβ is perturbed to favor the R state. Two explanations for this observation are plausible: (1) the T- 
state has been destabilized as a consequence of the manipulation of the Hb backbone topology, 
and/or (2) the α1β2 interface between heterodimers has been significantly destabilized, promoting 
the dissociation of the α1β1 heterodimers, which revert to an R state conformation in the absence of 
interactions across the α1β2 interface. Both analytical HPSEC and analytical ultracentrifugation (75) 
data show strong evidence that each of these mutants favor dissociation into dimers in oxygenated 
conditions and at lower protein concentrations.  
 The weakening of the α1β2 interface in the permuted Hbs is an expected consequence of 
permuting the β subunit. In the deoxy conformation of HbA, the α-carboxylate of β His146 forms a 




N- and C-termini in the cpβ-globin, the C-terminal α-carboxylate of β His146 is converted to an 
amide bond, thus removing the stabilizing salt bridge. To strengthen the tetramer, the Providence 
mutation (β K82D) was incorporated into the Hb mutants (6,17). In addition to the Providence 
mutation, the three mutations (β G16A, β H116I, and α G15A) were also integrated into the 
permutants to increase apoprotein stability (6). As shown in Figure 31, incorporation of the three 
stabilizing mutations into αcpβ results in improved ligand binding function. Expression yields for the 
Hb permutants also increased after the four stabilizing mutations were incorporated, as would be 
expected for a protein with increased stability (6,68). These improvements in expression yield and 
function demonstrated the desirability of generating a scHb that also contained the stabilizing 










Figure 31. Normalized time courses for full photolysis of 1 atm CO from HbA, αcpβ K82D 3sm, and 
αcpβ K82D 0sm. All experiments were conducted in CO-saturated 0.1 M potassium phosphate and 1 





Expression yields of scHb are approximately 5-fold lower than those for sc-αcpβ. Yet, even 
with the “tethers” that covalently link all four Hb subunits, there is evidence to suggest that the 
scHb folds to a structure that has the same packing of the subunits as is found in HbA. The UV-visible 
spectrum of sc-Hb (Figure 25) shows that the environment surrounding the heme retains a fold 
similar to wild-type Hb. 1H NMR provides evidence to support the same conclusion. Wild-type Hb 
and scHb have similar spectra in the upfield region, with analogous peaks corresponding to proton 
shifts (-2.5 ppm) from the heme porphyrin ring (Figure 27). However, the peak at -2.5 ppm is 
attenuated for scHb compared to wild-type Hb. This may be due to the orientation of the heme (70). 
Wild-type Hb strongly favors one heme orientation over the other, but non-specific heme 
orientation has been observed in our Hb and Mb constructs (71). The downfield region of the 1H 
NMR spectra contains peaks that correlate with the amide backbone and aromatic residues. There 
are similar resolvable peaks in this region between the two spectra that arise from NεH resonances 
of α103His and α122His side chains that span the α1β1 interface, which indicate that this interface 
remains relatively unperturbed in scHb.        
 Investigation of ligand binding showed that scHb has similar reactivity to HbA in the R-state, 
but an increased reactivity (i.e., faster on rates) in the T-state. This finding is consistent with ligand 
binding data obtained with αcpβ and sc-αcpβ. However, compared to αcpβ and sc-αcpβ, scHb has 
slightly increased amplitude in the T-state (Table 7). This observation is probably related to the 
quaternary state of the protein at the moment of photolysis. αcpβ and sc-αcpβ primarily exist as 
heterodimers at the concentrations used for photolysis studies, in contrast to scHb which exists as a 
covalent tetramer. In order for αcpβ and sc-αcpβ to transition into a T conformation, they must first 
associate to form a tetramer, which occurs at a slower rate than the recombination with ligand. 
Because scHb exists as an obligate tetramer at the moment of photolysis, it eliminates the transition 




conformation before recombination of ligand to the R-state occurs. It is disappointing that this 
proximity effect does not promote greater stabilization of the T state in scHb. This suggests that 
even though scHb is an obligate tetramer, the T-state is not favored under deoxy conditions (as it is 
for HbA). Heterodimer dissociation has also been observed in kinetics studies with HbA. Antonini et 
al. determined that fully liganded HbA dissociates into heterodimers with an equilibrium constant of 
K4,2 = 2-10 μM (72). In flash photolysis experiments with 5 μM HbCO, which includes a significant 
population of heterodimers at this concentration, the amplitude in the T conformation decreases 
compared to photolysis with 20 μM HbCO (64). Although the T-state amplitude of scHb is still 
significantly reduced compared to HbA, there is evidence to suggest that stable quaternary contacts 
made between the four subunits of scHb assist in the formation of the T-state. Current work in our 
lab is directed at increasing the stability of the T conformation in permuted Hbs.     
 Significant differences were observed between previous and current equilibrium oxygen 
binding studies of Hb mutants from our lab. Figure 16 shows equilibrium binding data collected in 
2011 under similar conditions to equilibrium binding data collected in 2013 (Figure 29). The most 
significant differences between the data sets are the - P50 values for the permuted Hbs. The current 
data possess P50 values that are markedly closer to HbA. These differences are likely due to the 
incorporation of the three stabilizing mutations in the current generation of Hb mutants in our lab. 
Figure 31 shows that αcpβ K82D 0sm (i.e., this mutant does not include the three stabilizing 
mutations) has an even more dominant fast phase than αcpβ K82D 3sm, implying that αcpβ K82D 
0sm has an increased ligand affinity, or more R-state character. This is reflected in the approximate 
1.5-2 fold increase in P50 values observed for the current generation of 3sm mutants compared to 




 Ideally, scHb should possess a physiologically appropriate O2 affinity, cooperativity, limited 
scavenging of NO, and a minimal autooxidation rate. Maillett et al. investigated a series of 
mutations that modulate some of these traits (61). Two of the mutations of interest include β N108K 
and α V96W. The β N108K mutation (also known as the “Presbyterian” mutation) has the following 
effects in rHb: increased Bohr effect (i.e., increased H+ binding), decreased O2 affinity, and the ability 
to switch to the T conformation without changing ligation state (61). The α V96W mutation located 
in the α1β2 interface was found to increase P50 without compromising cooperativity (61). 
Additionally, an rHb incorporating both N108K and V96W displayed synergistic effects compared to 
the single mutation variants (61). For these reasons, we incorporated these two mutations in αcpβ 
K82D 3sm to assess whether these effects would be manifested in our permuted Hb constructs 
(αcpβ N108K K82D 3sm, αcpβ V96W K82D 3sm, and αcpβ 6MT, where “6MT” = 3sm + K82D + N108K 
+ V96W). Flash photolysis and stopped-flow studies shown in Figure 32 indicate that αcpβ N108K 
enhanced both the rate and amplitude for ligand binding to the T-state (k’T), whereas αcpβ V96W 
and αcpβ 6MT increased k’T, but displayed a reduced amplitude for this slower phase than αcpβ 





Figure 32. Left: Normalized time courses for full photolysis of 1 atm CO from HbA, αcpβ, αcpβ N108K, 
αcpβ V96W, and αcpβ 6MT. All experiments were conducted in CO-saturated 0.1 M potassium 
phosphate and 1 mM EDTA, pH 7.0 at 20 oC. Right: Normalized time courses for stopped-flow 
measurement of 92.8 μM CO binding to deoxyHbA, deoxy αcpβ, deoxy αcpβ N108K, and deoxy αcpβ 
V96W (αcpβ 6MT not shown). Samples were prepared in 0.1 M potassium phosphate and 1 mM 
EDTA, pH 7.0, and data collected at 20 oC.          
 
Flash photolysis studies measured a k’T(CO) for αcpβ, which was approximately 2.8-3.5 fold 
higher than k’T(CO) for HbA (Table 7), and a k’T(CO) for αcpβ N108K that was only ~2-fold higher than  
that of HbA. In contrast, αcpβ V96W and αcpβ 6MT had greater than 5.5-fold increase for k’T(CO). 
These findings were consistent with data obtained by stopped-flow. Furthermore, equilibrium 
oxygen binding data indicate that αcpβ N108K is more cooperative than αcpβ. Cooperativities of sc-
αcpβ and scHb are nearly 2-fold less than HbA (Table 9). With the addition of N108K, the Hill 
constant for αcpβ increased to ~1.47, which is only 1.4-fold less than that for HbA (Figure 33). Based 
on these observations, it appears that the incorporation of N108K in scHb might confer improved 
functional properties, such as increased cooperativity, and marginally increased P50. In contrast to its 


















Figure 33. Fractional saturation with oxygen versus log of oxygen partial pressure (mm Hg) for HbA, 
scHb, and αcpβ N108K. Samples were prepared in 0.1 M potassium phosphate and 1 mM EDTA, pH 
7.0, and data was collected at 20 oC.     
 
The loss of cooperativity for the permuted Hbs could also be explained by oxidation of β 
Cys93 or β Met55. Others have observed the following effects as a result of oxidizing β Cys93 or β 
Met55 residues: (1) retention of native structure; (2) significant increase of ligand affinity; (3) 
decreased cooperativity (n ≈ 1); and (4) destabilized T-state (73). These observations are similar to 
those made with the permuted Hbs studied in our lab. ESI-MS yields an observed mass ~32 Da 
greater than expected for many of the permuteins purified in our lab. In the past we believed this 
mass increase to be a consequence of the well-known post translational methylation of rHbs (60); 
however, addition of dioxygen to Met or Cys would also account for this mass increase. Identifying 




contract analysis of our permuteins by a protein analytical lab, and/or Ala mutations at these sites. If 
S atom oxidation is an issue for these proteins, it is possible the functional characteristics that have 
been observed in our mutants (i.e. increased ligand affinity, decreased cooperativity, etc.) can be 
corrected by altering fermentation conditions to a less oxidizing environment prior to cell harvest.           
 For scHb to be considered as a scaffold for a therapeutically useful HBOC, it must first satisfy 
ideal functional and structural qualities described above. Inclusion of the β N108K mutation holds 
promise for stabilization of the T-state conformation as well as increasing cooperativity in scHb. 
Additional challenges include improving expression yields and apoprotein stability, and efficient, 
controlled, polymerization of scHb to yield higher order oligomeric states (illustrated schematically 
in Figure 18).  
There are many potential advantages to creating a polymerized scHb. A recent study of 
ultrahigh molecular weight polymerized bovine Hbs (bHb) by Buehler et al. describes the in vivo 
effects of poly-Hb infusion on guinea pigs (35). In this study, bHbs polymerized in either the T-state 
or the R-state were fractionated to isolate molecular weights >500 kDa. The P50 of polymerized T-
state bHbs was approximately 41 mm Hg and the P50 of R-state poly-bHb was approximately 0.66 
mm Hg (35). The cooperativities of both poly bHbs were < 1 (35). The T-state poly-bHb autoxidized 
at a slower rate than R-state poly-bHbs in vivo, and also had a longer circulatory half-life (35). The 
significant findings are that both polymerized bHbs possessed high viscosities and low colloid 
osmotic pressures, prolonged circulatory half-life, and limited poly-bHb dissociation. In a similar 
study, Cabrales et al. reported the pressor response in hamsters after the introduction of T-state 
poly bHb both above and below 500 kDa (37). This study showed that poly-bHb >500 kDa 
attenuated mean arterial pressure compared to poly-bHb <500 kDa (Figure 34). Additionally, poly-




showed greater attenuation of mean arterial pressure (37). These outcomes are similar to those 
described by Marquardt et al. for a monodisperse ~260 kDa tetra-Hb, and reinforce the idea that 






























Figure 34. Relative changes from baseline in arteriolar diameter after infusion of PolybHb at varying 
concentrations. A: PolybHb fractions with molecular mass <500 kDa. B: PolybHb fractions with 
molecular mass >500 kDa (37). 
  
 Ideally, polymerized scHb will be expressed by a single gene in E. coli. In that case the use of 
chemical crosslinkers will not be needed, resulting in reduced production costs, as well as yielding a 
monodisperse MW (i.e., the resulting poly-Hb will have a single optimized MW). A second approach 
to increase the size of an HBOC involving scHb is to form a covalent linkage to another protein such 




protein complex with SOD would have the advantage of eliminating superoxide radicals, which are 
generated during the reperfusion of ischemic tissues using whole blood (74).  
In conclusion, scHb represents a significant achievement in globin protein engineering- it is 
the first example of a single-chain Hb, and based on preliminary structural and functional data, scHb 
is a promising scaffold for the next generation of HBOCs developed in our lab.  
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